Artificial Intelligence in The Diagnostic Global Market Report 2024

The artificial intelligence in the diagnostic market size has grown exponentially in recent years. It will grow from $3.06 billion in 2023 to $4.29 billion in 2024 at a compound annual growth rate (CAGR) of 40.3%. The growth observed during the historical period can be attributed to several factors, including a rising disease burden, increased availability of data, efforts towards cost reduction, regulatory support, and an increase in awareness regarding the potential benefits of AI in diagnostics.

The artificial intelligence in the diagnostic market size is expected to see exponential growth in the next few years. It will grow to $16.24 billion in 2028 at a compound annual growth rate (CAGR) of 39.5%. The anticipated growth in the forecast period can be attributed to trends in personalized medicine, a rapid increase in healthcare data, global health challenges, heightened investments in AI in diagnostics, and enhanced integration with healthcare systems. Major trends expected in the forecast period encompass increased collaboration and investment in AI diagnostics, advancements in technology, concerns related to data privacy and security, the rise of explainable AI (XAI), and the expanding role of computer vision in diagnostic applications.

The anticipated growth of AI in the diagnostics market is attributed to the increasing prevalence of chronic diseases. Chronic diseases, characterized by their prolonged duration, present a persistent health challenge lasting for an individual's lifetime. The integration of AI-based diagnostic processes in managing chronic diseases offers advantages such as early detection, prediction, improved decision support systems, remote patient monitoring, cost reduction, and personalized treatment plans tailored to individual patients based on their genetic makeup and disease progression. As of September 2023, the World Health Organization reported 41 million annual fatalities, constituting 74% of global non-communicable disease (NCD) or chronic disease-related deaths. Notably, cardiovascular diseases accounted for 17.9 million deaths, cancer for 9.3 million deaths, chronic respiratory diseases for 4.1 million deaths, and diabetes for 2 million deaths. Therefore, the escalating prevalence of chronic diseases is a key driver behind the growth of AI in the diagnostics market.

Major companies in the AI in diagnostics market are actively engaged in developing cutting-edge technologies, including AI modules, to enhance their market competitiveness. An AI module, defined as a self-contained software component housing specific AI capabilities or functionalities, plays a pivotal role in this landscape. For example, in March 2023, Qritive, a Singapore-based provider of AI-powered solutions, introduced QAI Prostate, designed for prostate cancer diagnosis. This innovative solution efficiently identifies the most common form of prostate cancer, potentially enhancing diagnostic accuracy and reducing false positives. QAI Prostate assists pathologists in distinguishing cancerous from non-cancerous tissue areas, facilitating informed treatment decisions. Additionally, the tool streamlines case prioritization for faster diagnosis and reporting, contributing to improved efficiency and patient care.

In November 2021, Nanox Imaging Ltd., an Israel-based medical imaging technology company, completed the acquisition of Zebra Medical Vision Ltd. for $110 million. This strategic move positions Nanox to provide networked radiologists with robust AI algorithms supporting its systems. Zebra Medical Vision Ltd., based in Israel, is recognized for its expertise in AI-based medical imaging analytics and diagnostics.

Major companies operating in the artificial intelligence in the diagnostic market report are Google LLC, Microsoft Corporation, Intel Corporation, IBM Corporation, Siemens Healthineers, Koninklijke Philips N.V., GE Healthcare Technologies Inc., Paige.AI Inc., HeartFlow Inc., Aidoc Medical Ltd., AliveCor Inc., Butterfly Network Inc., Imagen Technologies, Digital Diagnostics Inc., Brainomix Ltd., NovaSignal Corp., Enlitic Inc., Nano-X Imaging LTD., EchoNous Inc., Zebra Medical Vision Ltd., Aidence B.V., Neural Analytics Inc., IDx Technologies Inc., icometrix N.V., Vuno Inc.

North America was the largest region in the artificial intelligence in diagnostics market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the artificial intelligence in the diagnostic market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the AI in diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The AI in diagnostics market consists of revenues earned by entities by providing services such as medical imaging analysis, disease prediction, and genomic sequencing analysis. The market value includes the value of related goods sold by the service provider or included within the service offering. AI in diagnostics market also includes sales of AI-powered imaging systems, AI-driven pathology tools, and point-of-care diagnostic devices Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

AI in diagnostics involves the application of artificial intelligence (AI) technologies in medical diagnosis, utilizing advanced algorithms, machine learning, and data analysis techniques to interpret medical data, images, and clinical information. The purpose of implementing AI in diagnostics is to enhance the accuracy, speed, and efficiency of medical diagnoses.

The primary components of AI in the diagnostic market include hardware, software, and services. Hardware pertains to the physical parts of a computer system or other electronic device. In AI in diagnostics, hardware plays a crucial role in improving processing power, enabling real-time analysis, ensuring scalability, facilitating integration with imaging devices, enhancing energy efficiency, ensuring security, promoting interoperability, customization, and reliability. These factors collectively contribute to more effective and efficient diagnostic processes in healthcare. Various technologies, including machine learning, natural language processing (NLP), context-aware computing, and computer vision, find application in various diagnostic types such as radiology, pathology, cardiology, oncology, neurology, chest and lung, among others.

The artificial intelligence in the diagnostic market research report is one of a series of new reports that provides artificial intelligence in the diagnostic market statistics, including the artificial intelligence in the diagnostic industry global market size, regional shares, competitors with artificial intelligence in the diagnostic market share, detailed artificial intelligence in the diagnostic market segments, market trends and opportunities, and any further data you may need to thrive in the artificial intelligence in the diagnostic industry. This artificial intelligence in the diagnostic market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.